NO20065471L - Anvendelse av IL-6 for behandling eller forebygging av kjemoterapiindusert nevropati. - Google Patents

Anvendelse av IL-6 for behandling eller forebygging av kjemoterapiindusert nevropati.

Info

Publication number
NO20065471L
NO20065471L NO20065471A NO20065471A NO20065471L NO 20065471 L NO20065471 L NO 20065471L NO 20065471 A NO20065471 A NO 20065471A NO 20065471 A NO20065471 A NO 20065471A NO 20065471 L NO20065471 L NO 20065471L
Authority
NO
Norway
Prior art keywords
prevention
treatment
chemotherapy
induced neuropathy
cipn
Prior art date
Application number
NO20065471A
Other languages
English (en)
Norwegian (no)
Inventor
Michel Dreano
Pierre-Alain Vitte
Original Assignee
Applied Research Systems
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Research Systems filed Critical Applied Research Systems
Publication of NO20065471L publication Critical patent/NO20065471L/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/20Interleukins [IL]
    • A61K38/204IL-6
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18Growth factors; Growth regulators
    • A61K38/185Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/54Interleukins [IL]
    • C07K14/5412IL-6
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NO20065471A 2004-04-29 2006-11-28 Anvendelse av IL-6 for behandling eller forebygging av kjemoterapiindusert nevropati. NO20065471L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL16167304A IL161673A0 (en) 2004-04-29 2004-04-29 Compositions and methods for therapy of chemotherapy-induced neuropathy
PCT/IL2005/000444 WO2005105135A1 (fr) 2004-04-29 2005-04-28 Il-6 pour traitement ou prevention d'une neuropathie induite par une chimiotherapie

Publications (1)

Publication Number Publication Date
NO20065471L true NO20065471L (no) 2007-01-09

Family

ID=34074041

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20065471A NO20065471L (no) 2004-04-29 2006-11-28 Anvendelse av IL-6 for behandling eller forebygging av kjemoterapiindusert nevropati.

Country Status (11)

Country Link
US (1) US7951359B2 (fr)
EP (2) EP3124040B1 (fr)
JP (1) JP2007534746A (fr)
AU (1) AU2005237324A1 (fr)
CA (1) CA2564390A1 (fr)
DK (2) DK3124040T3 (fr)
ES (2) ES2788131T3 (fr)
IL (2) IL161673A0 (fr)
NO (1) NO20065471L (fr)
PL (2) PL3124040T3 (fr)
WO (1) WO2005105135A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL163856A0 (en) 2004-09-01 2005-12-18 Applied Research Systems Use of IL-6 in vascular complications
US8372389B2 (en) 2007-11-28 2013-02-12 Hadasit Medical Research Services And Development Ltd. Methods for the treatment of radiation or chemotherapy-induced tissue damage
WO2012037283A2 (fr) * 2010-09-14 2012-03-22 Mount Sinai School Of Medicine Administration d'agents neuroprotecteurs du sns pour favoriser la régénération hématopoïétique
EP3299032A1 (fr) 2016-09-23 2018-03-28 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Inhibiteurs de gpr132 destinés à être utilisés dans la prévention et/ou le traitement de la douleur neuropathique induite par chimiothérapie
WO2019221528A1 (fr) * 2018-05-17 2019-11-21 Helixmith Co., Ltd. Traitement de la douleur neuropathique associée à une neuropathie périphérique induite par une chimiothérapie
WO2022256688A1 (fr) * 2021-06-04 2022-12-08 Sonnet BioTherapeutics, Inc. Méthodes de traitement de la fragilité liée à l'âge avec de l'interleukine-6

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4737462A (en) 1982-10-19 1988-04-12 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β
US4588585A (en) 1982-10-19 1986-05-13 Cetus Corporation Human recombinant cysteine depleted interferon-β muteins
US4959314A (en) 1984-11-09 1990-09-25 Cetus Corporation Cysteine-depleted muteins of biologically active proteins
US5116943A (en) 1985-01-18 1992-05-26 Cetus Corporation Oxidation-resistant muteins of Il-2 and other protein
US5017691A (en) 1986-07-03 1991-05-21 Schering Corporation Mammalian interleukin-4
US4879111A (en) 1986-04-17 1989-11-07 Cetus Corporation Treatment of infections with lymphokines
US4965195A (en) 1987-10-26 1990-10-23 Immunex Corp. Interleukin-7
US4904584A (en) 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
AU645294B2 (en) 1989-12-22 1994-01-13 Merck Serono Sa Endogenous gene expression modification with regulatory element
KR100234520B1 (ko) 1991-01-18 1999-12-15 그레고리 아보트 종양괴사인자 매개병 치료용 의약품 조성물
IT1247484B (it) 1991-03-22 1994-12-17 Ceinge Societa Consortile A R Metodo per la preparazione di interleuchina 6
WO1994003492A1 (fr) 1992-08-06 1994-02-17 The University Of Melbourne Variantes de l'interleukine-6 et leurs utilisations
IT1263022B (it) 1992-11-06 1996-07-23 Angeletti P Ist Richerche Bio Interleuchina-6 mutante con attivita' biologica migliorata rispetto all'interleuchina-6 selvatica.
IT1261787B (it) 1993-06-23 1996-06-03 Angeletti P Ist Richerche Bio Metodologia per la selezione di superagonisti, antagonisti e super- antagonisti di ormoni del cui complesso recettoriale fa parte gp 130.
US5635599A (en) 1994-04-08 1997-06-03 The United States Of America As Represented By The Department Of Health And Human Services Fusion proteins comprising circularly permuted ligands
WO1997016202A1 (fr) * 1995-10-27 1997-05-09 Amrad Operations Pty. Ltd. Cytokines et leur utilisation dans le traitement et/ou la prophylaxie du cancer du sein
ATE403001T1 (de) * 1996-05-22 2008-08-15 Viventia Biotech Inc Antigenbindungsfragmente die spezifisch krebszellen nachweisen, nukleotide die für diese fragmente kodieren, und deren verwendung zur vorbeugung und zum nachweis von krebs
CA2281493A1 (fr) * 1997-02-20 1998-08-27 David S. Dime Administration de medicament a specificite de site
IT1291932B1 (it) * 1997-06-20 1999-01-21 Angeletti P Ist Richerche Bio Composizioni farmaceutiche antitumorali capaci anche di ridurre la farmacoresistenza in cellule tumorali, in particolare di carcinoma
IL122818A0 (en) 1997-07-10 1998-08-16 Yeda Res & Dev Chimeric interleukin-6 soluble receptor/ligand protein analogs thereof and uses thereof
WO2001003737A1 (fr) 1999-07-13 2001-01-18 Bolder Biotechnology Inc. Proteines de fusion d'immunoglobine
WO2003033015A1 (fr) * 2001-10-11 2003-04-24 Applied Research Systems Ars Holding N.V. Utilisation d'activateurs de gp130 dans la neuropathie diabetique
IL163856A0 (en) * 2004-09-01 2005-12-18 Applied Research Systems Use of IL-6 in vascular complications

Also Published As

Publication number Publication date
DK3124040T3 (da) 2020-04-20
WO2005105135A8 (fr) 2006-12-07
US20080193409A1 (en) 2008-08-14
EP1740200B1 (fr) 2017-11-22
PL3124040T3 (pl) 2020-08-24
EP3124040A1 (fr) 2017-02-01
JP2007534746A (ja) 2007-11-29
ES2657049T3 (es) 2018-03-01
IL178636A0 (en) 2007-02-11
PL1740200T3 (pl) 2018-04-30
WO2005105135A1 (fr) 2005-11-10
ES2788131T3 (es) 2020-10-20
DK1740200T3 (en) 2018-01-08
CA2564390A1 (fr) 2005-11-10
EP3124040B1 (fr) 2020-02-12
AU2005237324A1 (en) 2005-11-10
EP1740200A1 (fr) 2007-01-10
IL161673A0 (en) 2004-09-27
US7951359B2 (en) 2011-05-31

Similar Documents

Publication Publication Date Title
NO20064584L (no) Tetrahydropyridoindolderivater
NO20092637L (no) Fremgangsmater for behandling
NO20064547L (no) Fremgangsmater for behandling av HIV infeksjon
DK2026803T3 (da) Sammensætninger af R(+) og S(-) pramipexol og fremgangsmåder til anvendelse heraf
GEP20125565B (en) Lactam compounds and their pharmaceutical use
NO20064325L (no) Heteroarylaminopyrazolderivativer nyttige for behandling av diabetes
NO20072733L (no) Doseformer
RS53128B (en) Extending the time of disease progression or survival in patients with ovarian cancers using PERTUZUMAB
GEP20084452B (en) Sulfonamide derivatives for the treatment of diseases
NO20064186L (no) Substituerte pyrazolin sammensetninger for a redusere triglycerider i blod
ATE416177T1 (de) Hetaryloxy-substituierte phenylaminopyrimidine als rho-kinasehemmer
MX2007007781A (es) Composiciones cardiovasculares.
DE602005021770D1 (de) Indol-1-yl-essigsäurederivate
NO20082120L (no) Behandling og forebyggelse av mikroangiopati
MX2009007337A (es) Indazoles sustituidos con 5-piridinona.
MX2009000285A (es) Piperidinas sustituidas que incrementan la actividad de p53 y usos de las mismas.
CY1112383T1 (el) Αναστολεις της πρωτεϊνης ενεργοποιησης της 5-λιποξυγενασης (flap)
MA28935B1 (fr) Preparation et utilisation de derives de biphenyl-4-yl-carbonylamino-acide dans le traitement de l'obesite
EA200800762A1 (ru) Предотвращение гипотензии и стабилизация кровяного давления у гемодиализных пациентов
EA200801997A1 (ru) Новые соединения
EA200800206A1 (ru) Комбинированное применение метконазола и эпоксиконазола для уменьшения или предотвращения заражения зерновых культур микотоксинами
NO20084826L (no) Ny administrasjonsform av racecadotril
NO20065471L (no) Anvendelse av IL-6 for behandling eller forebygging av kjemoterapiindusert nevropati.
EA201000329A1 (ru) Циклические депсипептиды
TW200716088A (en) Formulations and methods for treating amyloidosis

Legal Events

Date Code Title Description
CREP Change of representative

Representative=s name: ONSAGERS AS, POSTBOKS 6963 ST OLAVS PLASS, 0130 OS

FC2A Withdrawal, rejection or dismissal of laid open patent application